Takeda/Tigenix’ stem cell therapy hits targets in Crohn’s trial
Takeda and TiGenix’ stem cell therapy has shown promise in inducing remission of perianal fistulas in patients with Crohn’s disease, according findings of a late-stage trial published in The Lancet.
Read More
